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Guidance for Safety and Dosing of Medicines in Patients With 
Cirrhosis Is Available
TO THE EDITOR:
We read with great interest the article by Hayward 
et al.(1) describing medication-related problems 
(MRPs) in patients with decompensated cirrhosis. 
They found 375 MRPs among 57 patients random-
ized to a pharmacist-led intervention. Almost half of 
these MRPs possessed a high risk of potential harm 
to the patient and led to a higher rate of unplanned 
admissions.
The patients included in their study used various 
medicines in complex regimens.(1) The vast majority of 
these medicines were used for conditions other than the 
chronic liver disease and were not prescribed by gastroen-
terologists. We agree with the authors that management 
and monitoring of patients with cirrhosis is challeng-
ing and that physicians may benefit from prescription 
guidance. We disagree with their statement that a list of 
potentially inappropriate medicines for decompensated 
cirrhosis is lacking. While such guidance was absent at 
the start of their study, we published practical guidance 
for the safe use of over 200 medicines for patients with 
cirrhosis in 2018 in a paper that is freely available (https :// 
www.drugs inliv ercir rhosis.org).(2)
This guidance consists of advice on the use of a 
medicine in patients with cirrhosis (e.g. “can be used” 
or “avoid the use”) and, if necessary, joined by a dos-
ing recommendation.(2) It includes some well-known 
potentially inappropriate medicines (e.g., nonsteroidal 
anti-inflammatory drugs). It also includes medicines 
that have less known inappropriateness in cirrhosis, 
such as sertraline. Exposure to sertraline is 4 times 
higher in patients with compensated cirrhosis com-
pared to healthy controls, and exposure is predicted 
to increase even more in decompensated cirrhosis.(3) 
This endorses that guidance for prescribing is able to 
assist prescribers managing non-liver-related comor-
bidities in these patients.
We also studied the potential impact of our guid-
ance in a retrospective real-world study of patients with 
cirrhosis. Potentially unsafe medications were pre-
scribed in 60% of the 5,618 included patients during 
follow-up.(4) We have not studied the impact of our 
guidance in a prospective study or on actual patient 
outcomes. An interesting approach would be to com-
bine application of our guidance with a medication 
review, as described by Hayward et al., and examine 
the effect on hospital admissions and mortality.
In conclusion, tailored pharmacotherapy is needed 
in cirrhosis, especially in patients with decompensated 
cirrhosis as they are susceptible to MRPs. Prescribers 
can be supported by practical guidance on safe pre-
scribing and a high-quality medication review.
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